Dumolon, Lunabeth .
HRN: 22-20-09 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/27/2022
CO-AMOXICLAV 625MG (TAB)
12/27/2022
01/02/2023
PO
625
Bid
RMLE
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes